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Abstract
Inflammation is an immediate response to damage; in acute phase, it is a form of defense 
for body and it aims to restitutio ad integrum, in the chronic form itself becomes dis-
ease. This mechanism determines inflammatory diseases that are a group of clinical 
disorders which are characterized by abnormal inflammatory responses such as osteo-
arthritis, in myalgic syndromes (like fibromyalgia or miofascial sindrome), in some 
forms of headache, in peripheral vascular disease, in many malignancies. In Physical 
and Rehabilitation Medicine, the use of analgesic drugs (including NSAIDs) is a crucial 
resource inside a complex bioprogressive rehabilitative project. A part of the classic use 
per os is characterized by a serious and systemic side effect and there is also a possibil-
ity to administer drugs through other routes. Antalgic and rehabilitative mesotherapy 
(ARM) is a minimally invasive technique consisting of subcutaneous injections of bio-
active substances. Other alternatives are represented by iontophoresis, phonophoresis, 
phytotherapy, and topical application. The purpose of this chapter is to give an over-
view about the state of the art regarding the use of NSAIDs in physical medicine and 
rehabilitation.
Keywords: NSAIDs, antalgic and rehabilitative mesotherapy, iontophoresis, phonophoresis, 
phytotherapy
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1. Inflammation
Inflammation is an immediate response to damage to tissues and cells by pathogens, nox-
ious stimuli such as chemicals, or physical injury. Already in the short-term, there is an 
attempt at healing with white blood cells that arrive in the damaged area for repair process. 
Chronic inflammation, indeed, is a prolonged response that involves active inflammation, 
tissue destruction, and delays repair. Chronic and persistent inflammation is associated 
with many chronic human conditions and diseases, including allergy, atherosclerosis, can-
cer, arthritis, and autoimmune diseases. Acute inflammation is characterized by abrupt 
onset, followed by a rapid succession of events (hours or days) essentially vascular (hence 
angiophlogosis) responsible for the cardinal signs, culminating in the resolution or chro-
nicity. Chronic inflammation has greater duration of the previous form (months or years), 
with oscillations of the gravity and phenomena of intensifcation during its evolution. It is 
also defined as istophlogosis, for the prevalence of tissue phenomena due to infiltration 
of mononuclear blood cells [1]. The cardinal symptoms of inflammation, described by the 
Roman physician Aulus Cornelius Celsus (30 before Christ -  38 Anno Domini), are: calor, 
rubor, tumor, dolor, who later Galen (130–200 AD) added functio laesa, indicating the func-
tional impairment.
Inflammation process is a reaction triggered by innate immunity mechanisms, which evolved 
in a pattern that can vary based on etiologic agent, the headquarters of the damage and the 
intensity of the damage.
The mechanism underlying inflammation process is connected to the physiological state of 
homeostasis. Several studies suggest that inflammation operates as a much-sophisticated 
system than ever thought at the molecular level. The inflammation is mainly a local reaction, 
which generates a systemic response when it exceeds a certain threshold and molecules, 
synthesized and released into bloodstream in response to the damage, acting on distant 
organs that express receptors for them. As longer this response persists in the host will 
encounter the more damaging consequences [2]. Increased vascular permeability, that is a 
feature of acute inflammation, leading to the leakage of a protein-rich fluid (exudate) in the 
interstitium, to this, follows a variation of interstitial pressure (increases) and intravascu-
lar pressure (decreases). The presence of exudate and the hydrostatic pressure difference, 
draws fluid in the interstitial tissue with net result of edema. The first cellular step is repre-
sented by inflammatory stimuli that are first recognized by the host cells through specific 
transmembrane receptors, called pattern recognition receptors (PRRs), which are expressed 
by cells of both innate and adaptive immune systems. PRRs are responsible for sensing 
the presence of infecting microorganisms as well as the incidence of any cellular injuries. 
Disintegration of the tissue cells affected (with relative release of intracellular substances) 
determines the mobilization, through the blood, of the immune cells that reach the site of 
the lesion to begin a defence and repair process (activities mediated by substances released 
by these same cells) [3].
Once activated the inflammatory response, we see the release of chemical mediators that 
quickly induce alterations in the microcirculation, i.e., the vessels interposed between the 
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small arteries and small veins, arterioles, capillaries and venules. Thus, it began the vascular 
phase of inflammation, characterized by vasodilation and increased permeability.
The cells of the host’s immunocompetent system also (among which should be mentioned 
macrophages, polymorphonuclear granulocytes, the mast cells, fibroblasts and platelets) 
contribute to the process. Subsequently, mediators such as bradicin, histamine, serotonin 
(5-HT, 5-HydroxyTriptamine), prostaglandins (prostaglandins (PGs), cytokines (includ-
ing Interleukin (IL) and tumor necrosis factor (TNF) and some nerve growth factors Fabric, 
including nerve growth factor (NGF), neurotrophic factor derived from glial cell line (GDNF) 
and the neurotrophic factor derived from the brain (BDNF), are released [4]. Furthermore, 
it must consider the role of cyclooxygenase 2 (Cox-2, cycle-oxygenase-2), enzymes that, by 
acting inside of fibroblasts, favour the production of PGs, which have a great importance in 
causing inflammation and the ache. To complete the process of the liberated substances and 
widespread during the inflammatory process, among these must be counted calcitonin gene-
related peptide (CGRP), which activates the nociceptors, and Nitric oxide (NO), gas with great 
ability to spread among tissues and responsible for the neurotoxic effects. A neurochemical 
response from the same nerve cells is involved in pain perception (neurogenic inflammation). 
The damaged cells release a large amount of chemicals, including, in particular, some ions 
(mainly hydrogen ions, H+, responsible for local acidosis) and adenosine triphosphate (ATP) 
[5, 6]. (Figure 1)
Figure 1. Inflammatory process.
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All these substances have an active role in the onset of pain, a phenomenon closely related to 
inflammation [7]. Since the sensory nerve endings possess a variety of receptors designed to 
bind with the inflammatory mediators, some of the freed molecules such as adenosine triphos-
phate and hydrogen ions, act on nociceptors, activating them directly and causing an immedi-
ate depolarization, starting a painful stimulus. Other substances, instead, act on other receptors 
that are not able to start the painful stimulus but which are capable of sensitizing nocicep-
tors, or to lower the activation threshold. While the first category of brokers, the depolarizing 
substances, causes pain, the second category, that of sensitizing substances, causes hyperal-
gesia. Among the substances that sensitize the receptors necessary to signal, there is the sero-
tonin (5-HT), which is commonly released from platelets and mast cells in damaged tissue and 
inflamed. It acts by activating two receptor subtypes (5-HT2 and 5-HT3 receptor), whose action 
is synergistic with that of the receptors for bradykinin and for PGs. An inflammatory process 
of a somatic structure is manifested in particular with pain of varying intensity in relation to 
the release of active chemical mediators on algo-sensitive endings. Spinal reflexes of defence, 
through an increase in skeletal muscle tension, and hyperactivity of the sympathetic, contribute 
to the alteration of the microenvironment and the maintenance of the effects on nociceptors. 
The ultimate step in the elimination of traumatic agents and necrotic cells is their degrada-
tion within neutrophils and macrophages, which occur most efficiently after activation of the 
phagocytes. An efficacy system of host defence minimizes the damage and finally it controls 
the end of process. In fact, inflammation declines simply because the mediators of inflamma-
tion have short half-lives, but also because stop signals are released, they block the process [8].
In this way, in fact, the switch of arachidonic acid’s metabolism acts toward the production 
of anti-inflammatory lipoxins, the release of transforming growth factor-β (TGF-β), an anti-
inflammatory cytokine, from macrophages and other cells; and the cholinergic discharge that 
inhibit the production of TNF in macrophages [9].
The acute inflammation turns into a chronic one, when the process of resolution fails. 
Pathological states characterized by chronic inflammation are still under investigation, because 
in the West there are a great number of patients with these conditions, and also because the 
mechanisms that underlie chronic inflammation are not yet well understood. Chronic dis-
eases, often, are not triggered by infections or pathogens and this make the understanding of 
their pathological processes much more complicated [10]. Chronic phlogosis is the cause of 
these conditions and it is not derived by xenobiotics, but it is generated by inflammatory cells 
that act against the host itself. This mechanism determines inflammatory diseases that are 
a group of clinical disorders which are characterized by abnormal inflammatory responses 
such as osteoarthritis, in myalgic syndromes (like fibromyalgia), in some forms of headache, 
in peripheral vascular disease, and in many malignancies [11].
2. From pathophysiology to pharmacology
The study of inflammatory pathophysiology was crucial stimulus to the search for substances 
pharmaceutically active on related symptoms. NSAIDs are mainly anti-inflammatory, but 
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also analgesic and antipyretic drugs. They are typically used in the treatment of pain, to 
reduce stiffness, and to enhance function in patients with musculoskeletal disorders, osteoar-
thritis, rheumatoid arthritis, and other forms of arthritis. Furthermore, NSAIDs are also used 
for the treatment of acute pain including headache, dysmenorrhea, and postoperative pain 
[12, 13].
Acetylsalicylic acid (ASA), better known as aspirin, is the prototypical NSAID. ASA traces 
its origins back to willow bark, a natural source of the chemical salicylate. All NSAIDs inter-
rupt the production of inflammatory and pain-related hormones called prostaglandins. 
The isolation of salicylic acid in the nineteenth century from willow and poplar barks led 
to its widespread use as an antipyretic, analgesic and anti-inflammatory agent. Since then, 
many nonsteroidal compounds with anti-inflammatory properties have been discovered. 
Since ASA’s introduction in 1897, more than two dozen chemically-related drugs have been 
developed. The group is generally restricted only to those substances that act by inhibiting 
components of the enzyme system in the metabolism of arachidonic acid and formation of 
eicosanoids. Key pharmaceutical class is that of NSAIDs, which act on the metabolism of ara-
chidonic acid, reducing the production of prostaglandins that intervene on the vascular phase 
of inflammation and sensitize nociceptors by lowering the activation threshold by algogenic 
substances. Prostaglandins’ synthesis part from phospholipids commonly contained in the 
membrane structure of all cells, which, by enzymatic action effect of phosphorylase, is trans-
formed into arachidonic acid: this molecule acting on the cyclooxygenases 1 and 2 (Cox-1 and 
Cox -2), which are responsible for the synthesis of PGs. PGs, in turn, act on the prostaglandin 
receptors (EP) and this activation is derived from a particular sensitization of nociceptors, 
able to produce hyperalgesia. Many common drugs used for joint pain, rheumatism, but also 
fever, act by inhibiting the COX-1 or COX-2, or both, and reducing, among other things, pain 
and hyperalgesia. The COX binds the NSAIDs on an arginine residue (ARG120) and from 
here the inhibitory part of the drug clutters the active site of “enzyme; in fact the” enzyme 
is bifunctional and has two active sites, one that transforms the “acid in PGG2 and another 
that turns this” last in PGH2, but NSAIDs inhibit the first of the two sites. It is a reversible 
competitive inhibition, with the exception of aspirin, which binds instead to Serina 530 with 
an irreversible bond. Its effect, therefore, lasts even after the deletion of the medication from 
body, as long as it is not synthesized new enzyme. The various NSAIDs, presently, can be 
divided on the basis of their selectivity to COX.
The COX-1 is a constitutive enzyme expressed in most cells, responsible for the physiologi-
cal production of prostanoids, ubiquitous mediators that, through the interaction of specific 
membrane receptors coupled with G proteins, are involved in intercellular communication 
and in the modulation of several homeostatic functions (gastric, platelets, kidney).
COX-2 is inducible isoform of the enzyme as a result of pro-inflammatory stimuli, mainly 
responsible for the production of prostanoid mediators of inflammation and in pain trans-
mission. However, in the CNS, kidney, prostate, testes, and vessels are COX-2 of constitu-
tive type. Inhibition of COX-2 by NSAIDs, should be responsible for the therapeutic effects, 
whereas inhibition of COX-1 would result in adverse reactions to these drugs. The COXIB are 
selective inhibitors of COX-2.
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NSAIDs are classified as in Figure 2.
It was estimated that about 100 million people worldwide use NSAIDs and therefore are 
the most widely used drugs ever, especially in the treatment of postoperative pain and pain 
related to musculoskeletal disorders (Berde and Sundel) such as rheumatoid arthritis or 
osteoarthritis [14].
Diclofenac has anti-inflammatory analgesic and antipyretic effect, and its power is greater 
than other NSAIDs. It is indicated for chronic inflammatory diseases such as rheumatoid 
arthritis and osteoarthritis at a dose of 100–200 mg/day. It is also used as analgesic in the case 
of musculoskeletal injuries, tendinitis, postoperative pain, and dysmenorrhea (50 mg). It is 
rapidly absorbed after oral administration and has a short half-life of 1–2 hours. A new salt 
of diclofenac, diclofenac epolamine, is highly effective as both an anti-inflammatory and an 
analgesic agent for its favourable permeation characteristics. Furthermore, recently, it is put 
commercially a new formulation of diclofenac injectable, diclofenac sodium together with 
cyclodextrins, which improves the solubility of diclofenac. It is a new pharmaceutical form in 
1 ml volume which offers not only the unique advantage of the subcutaneous administration 
(besides the “classical” intra-muscular injection) but also the use of the lowest dosage.
Ketorolac (LIXIDOL, Toradol): It is a potent analgesic and a moderate anti-inflammatory. Unlike 
opioid analgesics, it does not give tolerance, dependence, and respiratory depression. It uses 
intramuscular (30–90 mg) for the treatment of post-operative pain as an alternative to opioids.
It acts in the reduction of post-surgical pain (arthroplasty, disc herniations, femoral fractures 
with reduction). It is also used in the most difcult forms of dysmenorrhea, or for the treatment 
of renal colic sporadic and chronic.
Figure 2. Classification of NSAIDs.
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Treatment with ketorolac should not exceed 5 days to the possibility of serious complications 
gastric, haemorrhagic, and renal.
Ibuprofen (Brufen, MOMENT) is used as anti-inflammatory for rheumatoid arthritis, osteo-
arthritis, periarthritis, low back pain, sciatica at a dose of 2400 mg/day. At lower doses, it is 
devoid of anti-inflammatory activity and is used as an analgesic in various forms including 
painful headache and dysmenorrhoea (400 mg every 4–6 hours).
It has a short half-life of 1–2 hours; it is highly bound to plasma proteins and it does not inter-
act with anticoagulants.
Naproxen (ALEVE, FLOGINAX, Naprosyn, Naprosyn GEL, NAPRIUS, MOMENDOL, 
SYNFLEX). It has the same pharmacological profile and the same indications of ibuprofen. 
It is a well-tolerated drug. It has long half-life of 12–15 hours. The half-life is approximately 
doubled in elderly patients thus making it necessary dosage changes.
Ketoprofen (Fastum, Orudis): It inhibits both COX and LPX. This property does not make 
it superior than others NSAIDS. The efficacy of ketoprofen in the treatment of rheumatoid 
arthritis and osteoarthritis is similar to that of aspirin and other NSAIDs. It has a very 
short half-life of 1–2 hours; it is highly bound to plasma proteins, but does not modify the 
activity of warfarin and digoxin. Probenecid increases the plasma levels and prolongs the 
half-life [15].
The World Health Organization (WHO) in 1996 proposed a scale for pain assessment in the 
first instance oncological and later adopted as a guideline for the pharmacological treatment 
of musculoskeletal pain. This scale consists of three levels:
• Pain Mild (assessment of pain according to visual analogue scale—VAS from 1 to 4): it is 
suggested treatment with NSAIDs or acetaminophen ± adjuvants.
• Pain Mild to moderate (VAS 5-6): it is suggested treatment with weak opioids or NSAIDs ± 
paracetamol ± adjuvants.
• Pain Severe or moderate to severe (VAS 7-10): it is suggested treatment with strong opioids 
± NSAIDs or acetaminophen ± adjuvants [16] (Figure 3).
The chronic use of NSAIDs cause: coagulopathies (reduced platelet aggregation, increased 
bleeding time), gastrointestinal toxicity (gastritis and dyspepsia, ulcers, vomiting blood, diar-
rhoea), hepatotoxicity (increased transaminases, cholestatic hepatitis, acute hepatic necrosis), 
haematological effects (leukopenia, agranulocytosis, aplastic anemia), kidney effects (salt and 
water retention, azotemia, oliguria, interstitial nephritis, papillary necrosis, acute), respira-
tory effects (bronchospasm), allergy, dermatitis, headache.
NSAIDs interactions with other drugs: reduce the efficacy of beta-blockers, ACE-inhibitors 
and diuretics; increase the effect of sulfonylureas and toxicity of aminoglycosides and cyclo-
sporine. The COXIB, long-term, increases the risk of serious cardiovascular events and 
thrombosis, myocardial infarction, stroke; also, such as NSAIDs, increase the risk of serious 
gastrointestinal adverse effects (bleeding, ulceration and perforation), even in the absence of 
warning symptoms [17].
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To minimize or abolish the adverse effects of the oral administration of these drugs, there are 
several techniques used in physical and rehabilitation medicine, such as mesotherapy, ionto-
phoresis, phonophoresis, and last but not least, phytotherapy which uses natural substances 
with anti-inflammatory properties.
3. Antalgic and rehabilitative mesotherapy
Mesotherapy is based on the principle that intradermal therapy produces a “micro deposit” of 
the drug in the dermis which is then slowly released into the surrounding tissues. Nowadays, 
mesotherapy should be considered an increasingly important aspect of Interventional 
Physical and Rehabilitation Medicine (IPRM).
Mesotherapy consists of a series of “microinjections” of drug/active substance into the dermis 
using short needles where the needle is positioned at an appropriate angle depending on 
the thickness of the skin. A French physician, Michel Pistor, reporting encouraging results 
with small drugs administered intradermically to patients with a variety of clinical condition. 
He defines mesotherapy as a novel analgesic therapy for a variety of rheumatologic disor-
ders [18, 19]. The term mesotherapy derives from Greek (Mesos = “Medium” and Therapeia = 
“care”), and refers to the mesoderm germ layer from which are differentiated tissues and 
structures such as bone, cartilage, muscle and connective tissue. It makes superficial injections 
directly on the area above the structure affected by the disease, using a 27–33 gauge needle; 
typically administered are 0.10–0.20 ml of medication and injection points at 2–3 cm distance.
Figure 3. The World Health Organization (WHO) scale for pain assessment in the first instance oncological and later 
adopted as a guideline for the pharmacological treatment.
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Although the fundamental principles upon which mesotherapy are those expressed by 
Michel Pistor, mesotherapy concept evolved in recent years: from the concept of needle 
insertion in the point of greatest pain (such as trigger points) to injection of analgesic agents 
such as lidocaine or bicarbonate, [20, 21] arriving at the concept of mesotherapy as aspect of 
Interventional Physical and Rehabilitation Medicine (IPRM). The Interventional Physical and 
Rehabilitation Medicine (IPRM) is the possibility by physiatrist to insert in the individual 
rehabilitation project, with the most appropriate timing, an interventional procedure to sup-
port the conservative applied methods. In addition, mesotherapy is a procedure in which 
not only is it possible to introduce a specific drug, but it represents the possibility to choose 
whether to treat the point of maximum pain, the area of referred pain or functional damaged 
district. Depending on the needle technique used, it is possible to reach different tissues and 
different depths. The use of more deep techniques, associated with the administration of the 
drug, can interrupt the inflammatory cascade and it generates, as a result of the mechanical 
action of the needle, tissue repair processes with reduction of local fibrosis.
There are various techniques of mesotherapy that are different depending on the used needle 
length and gauge, the injected substance, the depth of penetration:
Intraepidermic (IED) in which the injection is carried out at the level of the epidermis-dermis 
junction at 1–2 mm depth with the needle parallel to the skin and the bevel of the needle faces 
upwards.
Nappagein in which is recommended a deeper injection at 2–4 mm with an angle of 
30–60 degrees. Usually two to four injections are carried out with a space of 3–4 mm between 
each point of injection.
Point-by-point (PPP) with a deep injections at 4 mm at most.
Mesoperfusion in which injections should be involved at 4–13 mm over 30–90 minutes.
The perfect drug for mesotherapy is the one whose technical data sheet covering three routes 
for parenteral administration. If a certain drug or association exists both intramuscular and 
intravenous version, the first is preferred, because the tissues of mesotherapy—epidermis, 
dermis and subcutaneous—have greater histochemical affinity with muscle rather than blood.
The most commonly used in mesotherapy drugs are NSAIDs (diclofenac, ketoprofen, aspi-
rin, ketorolac, piroxicam), muscle relaxants (thiocolchicoside, pridinolo mesylate), vasoactive 
drugs (mesoglycan), calcium chelators (EDTA) and local anesthetics (lidocaine, procaine). 
Diclofenac sodium together with ciclodextrins is a solution for injection can be administered 
intramuscularly or subcutaneously as mesotheraphy. It can be used in different doses: in case 
of mild or moderate pain, it is sufficient to use the lowest dose (25 mg). A dose of 50–75 mg 
may be required in case of severe pain. Exceptionally and in severe cases, it can be adminis-
tered a second dose of 75 mg after six hours. The maximum daily dose (24 hours) must not 
exceed 150 mg.
They should never be injected mesotherapy turbid drugs or frankly precipitating, since the 
crystals also of small size can obstruct thin blood capillaries and determine thrombosis and 
tissue necrosis. To avoid the reaction of acid-basic cocktail with opposite pH products, you 
Nonsteroidal Anti-inflammatory Drugs: Integrated Approach to Physical Medicine and Rehabilitation
http://dx.doi.org/10.5772/intechopen.69257
75
can load the syringe with the defined quantity of saline at the beginning of the preparation. 
Each cocktail drug must be diluted in physiological solution in the volumetric ratio of 1:10 or 
0.5 ml:5 ml. In mesotherapy it is prohibited inject oily and alcoholic solutions for the high risk 
of necrosis. Corticosteroids are contraindicated both individually and in cocktails because it 
can cause skin atrophy. In the case of extra-articular injections it is a side effect with estimated 
frequency from Brinks et al. [22] of around 1%, but with possible serious aesthetic impact, 
which in intradermal injections is likely much higher [23].
The risk of allergic reactions preclude the intradermal administration of a muscle relaxant 
plus a nonsteroidal anti-inflammatory agent in the same syringe as it is not possible to deter-
minate which drug has caused the allergy.
Protocols for mesotherapy allow to make one or more cycles depending on the symptoms, 
the severity of the disease and the patient’s response. In chronic painful conditions there are 
three distinct phases: attack (sevently weekly treatments are administrated), control (four 
fortnightly treatments are given to confirm results and prevent short-term recurrences) and 
maintenance phase (monthly or seasonal treatment). In resistant pain, twice weekly therapy 
is recommended in the “attack phase” depending on the analgesic effect obtained. There are 
several advantages of mesotherapy: the process of introducing needles into the skin stimu-
lates a reflex action thereby increasing endorphin levels, which blocks the painful sensation; 
the rapidity of action, related to the short time required to reach the site of action, as well as a 
prolonged local effect and a reduction of side effects.
The use of mesotherapy in Italy was approved by the Italian Society of Mesotherapy (SIM) 
in 1975, following a number of multi-center studies have confirmed the effectiveness of this 
method in the control of joint pain (hip/knee osteoarthritis/Hand, neck pain, back pain, ten-
donitis) (Figure 4).
In addition to the analgesic and anti-inflammatory effect, these studies have demonstrated the 
safety of administration and reduction of side effects compared to oral via.
The combined use of mesotherapy with physical therapy achieves a synergistic effect in mus-
cle injuries of athletes, control of neuropathic pain, inflammatory tendonitis, degenerative 
and/or calcified. The indication more appropriately, according to these studies, is treatment 
of musculoskeletal and osteo-articular pain. Open studies conducted with mesotheraphy 
approach in musculoskeletal pain such us arthritis, neck pain, lower back pain, and tendi-
nopathy show a reduction of pain at least 50% compared to pre-treatment [24–39].
Furthermore, literature reported that a great number of patients treated with mesotherapy 
for musculoskeletal pain disorders had rapid pain relief, generally when the patient responds 
within the first three sessions of therapy [40].
Costantino et al., started a study with the aim to compare mesotherapic versus conventional 
systemic administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and corticoste-
roids in patients with acute low back pain. They showed that the administration of NSAIDs 
and corticosteroids via mesotherapy can provide the same therapeutic benefit as that induced 
by conventional (oral and intramuscular) drug administration. The major aspect is the com-
parable effectiveness of mesotherapy and conventional systemic therapy, despite the lower 
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amount of drugs administered to patients undergoing mesotherapy (41.67% ketoprofen and 
50% methylprednisolone). Author concluded that subcutaneous drug administration results 
in a very slow drug absorption such as intramuscular and oral and that it could be assumed 
Figure 4. Mesotherapy in 1975, low back pain and sciatica.
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that anti-inflammatory substances, dispensed with mesotherapy, reach a high drug concen-
tration into the subcutaneous tissue and it acts locally close to the inflammatory cells, sensi-
tive fibers and vascular mediators that generate inflammation and pain [41].
Even in the case of carpal tunnel syndrome, diagnosed by clinical examination and neuro-
physiological investigation, it used a mixture containing lidocaine 10 mg, ketoprofen lysine-
acetylsalycilate 80 mg, xantinol nicotinato 100 mg, cyanocobalamin 1000 mcg more injectable 
water, injected above the transverse carpal ligament, at the base of the thenar and hypothenar 
eminence. It has noticed already after 24 hours, a significant reduction in pain and paresthe-
sias, which lasted up to 12 months in over 50% of the sample.
The mesotherapy with NSAIDs is applicable to several pathological conditions, as dem-
onstrated by several studies, starting from pes anserine bursitis, treated by Saggini et al. 
(Figure 5) with nine sessions of mesotherapy with diclofenac sodium (25 mg/1 ml; Akis, IBSA, 
Switzerland), 1 ml per session, three times a week. These patients’ outcome was assessed by 
visual analogue scale (VAS), along with the ability to perform activities of daily life, the abil-
ity to participate in sports, level of pain, symptoms, and quality of life. These measurements 
were performed before and after the treatment period and at 30 and 90 days of follow up. 
It was thus obtained with a significant reduction in pain after the treatment period; further 
Figure 5. Algorithm treatment of antalgic and rehabilitative mesotherapy. Center of Physical and Rehabilitation 
Medicine, “Gabriele d’Annunzio” University, Chieti- Chief R. Saggini md.
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ultrasound investigations showed a hypoechoic area reduction related to pes anserine bursitis 
only in the group receiving mesotherapy and not in the control group, treated, however, with 
oral therapy [42].
The mesotherapy is therefore an innovative technique specific of Interventional Physical 
and Rehabilitation Medicine (IPRM). It enables operation of painful conditions also chronic, 
inflammatory, degenerative, and traumatic diseases. This type of therapy, which can be 
defined “ecological,” fits perfectly into the global bioprogressive approach, where to work on 
the bone-myofascial system, this must be put in the control condition and reduction of pain, 
to optimize dynamics of the body and thus increase performance.
4. Iontophoresis
The method of iontophoresis has been described by Pivati in 1747. In the eighteenth cen-
tury, two illustrious scientists Galvani and Volta, joined together the principle by which elec-
trons’ movement generate electricity and that according to which electricity moves ions [43] 
(Figure 6). In the 1870s, the German Hermann Munk (1839–1912) extensively investigated the 
current mediated transport of substances, such as strychnine, through porous membranes. He 
then thought about transmitting drugs through intact human skin as the skin is some kind of a 
porous membrane as well. The strychnine experiments were repeated by the French physician 
Figure 6. Molecular transport during iontophoresis.
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Stéphane Leduc (1853–1939), showing that strychnine sulfate is transported from the positive 
to the negative pole of the electric circuit.
This phenomenon was intensively studied by Fritz Frankenhäuser (born 1868) who invented 
the term “Iontophorese” earlier than 1908 [44].
Iontophoresis is applied in physical medicine to treat musculoskeletal disorders such as 
osteoarthritis, bursitis, and tendinopathy by transdermal drug administration. It is a proce-
dure that uses the application of a constant voltage electricity to convey through the skin 
charged and highly polar molecules. Iontophoretic transport can occur by electrorepulsion 
or electromigration, but considering the properties of the skin, drug can be transported by 
electro-osmosis [45].
The migration of the therapeutic agent also depends on its charge: cationic or neutral sub-
stances are conveyed toward the anode, anionic substances are conveyed toward the cathode. 
Applying a low voltage current, following the principle dell'elettro repulsion, the ions are 
repelled through the skin. Since the skin is negatively charged under physiological condi-
tions, the electroosmotic flow is then from anode to cathode [46].
Restrictions about iontophoretic system, include law limits on the amount of current that can 
be used in humans (nowadays set to 0.5 mA/cmq) and the irreversible harm that such currents 
could do to the skin’s barrier properties. Furthermore, iontophoresis has not managed to sig-
nificantly improve the transdermal vehiculation of molecules >7000 Dalton [47].
The limit of mulecular size can be overcome with electroporation, i.e., the application of high 
voltage pulses to induce modifcations of skin.
Electroporation uses high voltages (≥100 V) for short treatment periods (milliseconds), which 
increase the skin permeability, probably for the generation of transient pores during electro-
poration. The result of electroporation is not always better than iontophoresis, but appears 
lasts longer. It depends on the energy of the electrical field [48]. (Figure 7)
Many factors influence the outcome of the transdermal delivery of drugs: physicochemical 
properties of the substance (charge, concentration, size of molecules), formulation (pH, viscos-
ity, presence of other ions), biological variation (age, sex, site of application, vascularization), 
body temperature, types of electrodes and current used, duration of the session. (Table 1)
The main advantage of the transdermal administration of drugs, is the increased bioavailabil-
ity of the active principle in absence of hepatic first-pass metabolism [49]. This hypothesis was 
tested for numerous NSAIDs in both in vitro and in vivo studies [50, 51]. In vitro, it has been 
demonstrated that piroxicam gel solution diffusion through the skin is 100–1000 fold higher 
applying iontophoresis for 6 hours, compared to the passive diffusion [52].
Also in vivo on man, it has been demonstrated this advantage of iontophoresis and it has been 
noticed a concentration of piroxicam in the stratum corneum significantly higher compared 
to the passive diffusion [53]. In another study in vitro, ketorolac has been convey through rat 
skin applying a current density from 0.11 to 0.15 mA/cmq with 10–100 fold increase than its 
passive vehiculation [54]. (Figure 8)
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Drug Polarity
Lysine acetylsalicylate Negative
Diclofenac sodium Negative
Indomethacin Negative
Piroxicam Negative
Ketoprofen Negative
Benzydamine hydrochloride Bipolar
Methyl nicotinate Positive
Phenylbutazone Positive
Glycol salicylate Positive
Table 1. Polarity of NSAIDs.
Figure 7. Electroporation.
Figure 8. Ultrasonography: reduction of a hypoechoic area (pes anserine)—pre (T0) and after (T1) the treatment period: 
30 days of transdermal diclofenac sodium 25 mg/ml with electroporation(Isofor Compact) for three times a week for three 
weeks with sessions lasting 20 minutes each. Center of Physical and Rehabilitation Medicine, “Gabriele d’Annunzio” 
University, Chieti- Chief R.Saggini MD.
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A series of studies reported anti-inflammatory effects of iontophoresis and electroporation 
in many common inflammatory conditions of the musculoskeletal system. All of the clinical 
investigations demonstrated at least positive clinical outcome [55–58].
One of the first studies on the transdermal drug delivery goes back to 1996 by Saggini et al. 
in the treatment of rheumatic pain with ketorolac compared with placebo. Seven days after 
the end of therapy, patients who received ketorolac have experienced a further reduction in 
pain (highly significant compared to pre-treatment values; P < 0.005). The best results were 
observed in patients who had severe or very strong pain at the beginning of treatment. The 
intensity of pain in patients who received placebo, returned to pre-treatment values [59].
Baskurt et al. conducted a study comparing the effectiveness of transcutaneous delivery of 
naproxen via iontophoresis versus phonophoresis. The results suggest that iontophoresis and 
phonophoresis of naproxen are equally effective electrotherapy methods in the treatment of 
lateral epicondylitis [60].
Demirtaş et al., suggest positive effect of iontophoresis in the treatment of lateral epicondylitis 
and indicate that iontophoresis of sodium diclofenac is more effective than that of sodium 
salicylate [61].
The effectiveness of this therapeutic method has also been tested in secondary painful events 
in arthritic disease of the spine. Patients were treated with diclofenac sodium and betameth-
asone for 20 minutes and evaluated immediately after the end of the treatment and after 
24 hours, by detecting a significant reduction of spontaneous pain after the application, which 
is maintained unchanged even at 24 hours [62]. Also in subjects with inflammatory disease, 
iontophoresis returns excellent results, as observed in subjects with inserted pes anserine bur-
sitis in a study, the purpose of which was to compare the efficacy of conventional oral therapy 
with anti-inflammatory, mesotherapy and (Isofor Compact) electroporation using the same 
substance. In all groups, we were obtained with similar results in terms of decrease in pain 
and improvement in quality of life at the end of the third week of treatment. However, the 
ultrasonography showed a hypoechoic area reduction of pes anserine bursitis only in the 
groups treated with mesotherapy and electroporation [63].
Moreover, iontophoresis appears a safe and applicable method in a complex rehabilitation proj-
ect, also in children, as in the case of osteochondrosis of the tibial tuberosity, inflammatory 
degenerative disease. The results showed a significant reduction in pain even after the first 
two weeks of treatment and pain relief in its third week. A significant improvement in the 
ultrasound examination at the end of the protocol with normalization of the patellar tendon 
thickness and peritendinous edema resorption, a symmetrization of the load at podobarometric 
examination and a significant improvement in the isokinetic test [64].
5. Phonoforesis
Another interesting method of treatment of Psychiatric and Rehabilitation Medicine is the 
phonophoresis, that consists in the use of ultrasound for transcutaneous drug delivery.
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Cutaneous bioavailability in most of the marketed dermatological formulations is low.
The skin represents a significant barrier to the entrance of foreign substances, but is also a 
potential therapeutic away.
The stratum corneum has a structure in determining barrier function. The corneocytes (about 
85% of the mass of the stratum corneum) and intercellular lipids (15%) are arranged in about 
15–20 layers [65]. It consists of approximately: 70% protein, 15% lipids, and only 15% of 
water [66]. In corneocytes, thickened keratin and filaggrin and cleavage products are pres-
ent. The corneocytes is rich in protein and is surrounded by lipids [67]. Weight ratio of 50% 
ceramides, 35–40% cholesterol, fatty acids liberi10–15% contained within the extracellular 
spaces and arranged in double layer slats make the stratum corneum impermeable to water 
soluble substances [68].
Changes of this lamellar structure and/or of its lipid composition constitute the biochemist 
and structural basis of permeability variations related to the body site.
It is possible to increase the penetration of active substances through the stratum corneum 
using ultrasound, reaching, thus, the area to be treated with the appropriate concentration 
of drug at a certain depth and in a selective way, without dispersion in bloodstream and first 
pass effect [69]. Ultrasound (US) produces alterations in the structure of the stratum corneum 
and increases the permeability [70]. (Figure 9)
Temperature increase induced by the US increases the kinetic energy of drug’s molecules, 
dilates the points of entry through the skin (hair follicles and sweat glands), and increases 
the blood flow in the treated area [71]. US also produce mechanical effects as microstrem-
ing and cavitation of cells, or in any case nonthermal effects as reduction of the membrane 
potential, alterations of lipid structure, with increased cell permeability and ionic conduc-
tance [72].
Cavitation refers to the formation and collapse of small air bubbles formed in a liquid due to 
a pressure change induced in the tissue fluid from the passage of ultrasound. (Figure 10 a - b)
Cavitation can be stable (when ultrasound of high intensity and low frequency passing 
through a liquid, produce small bubbles that oscillate rhythmically in size) or unstable 
(when high-frequency ultrasound generate bubbles that grow and collapse abruptly). 
(Figure 10 c - d)
Figure 9. Ultrsound characteristics.
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For microstreaming, it means the formation of vortices in small volumes of cytoplasmic and 
interstitial fluid; this improves the dissolution of the drug particles in suspension and alters 
the cell membrane structure by setting the permeability to sodium and calcium ions [73].
For a long time, effective frequencies have been investigated to produce therapeutic effect.
Ultrasound for therapeutic purposes, are used in physical and rehabilitation medicine with 
a range between 0.75 and 3 MHz: lower frequencies penetrate most deeply (3–5 cm) and 
are preferred in subjects with a high percentage of body fat, while higher frequencies are 
absorbed from superficial tissues (1–2 cm) (Figure 11).
In rehabilitation, phonophoresis is used to convey drugs such as corticosteroids and 
NSAIDs to treat diseases affecting the musculoskeletal system, such as osteoarthritis 
treated by Boyaci et al. with 100 mg of ketoprofen using an applicator 5 cm in diameter, 
with a frequency of 1 MHz, with a power of 1.5 W/cm2 for 8 min. Patients involved in the 
study were assessed before and after treatment with VAS scale, 15-m walking time, and 
Western Ontario and McMaster Universities Arthritis Index (WOMAC), and reported a 
significant improvement in their condition [74]. Also a study of Tascioglu et al. showed 
greater efficacy of pulsed mode than continuous mode in the treatment of osteoarthritis of 
the knee [75].
Luksurapan has instead used 20 mg of piroxicam in continuous mode, power, 1.0 W/cm2 in 
sessions from 10 minutes to treat the same disease, obtaining excellent results in particular 
relating to the VAS scale [76].
Another disease that can be treated with phonophoresis is the painful myofascial syndrome, 
treated with diclofenac gel (Voltaren emulgel) applied with an applicator 5 cm in diameter at 
1 MHz of frequency and power 1.5 W/cm2 for 10 minutes on two trigger points of the trape-
zius muscle, with improvement in pain compared to the baseline condition [77].
For temporomandibular joint (TMJ) pain phonophoresis with 1.0 MHz frequency, power 0.8 
to 1.5 W/cm2 in continuous mode for 15 minutes was applied, with results suggesting that 
transdermal delivery of indomethacin with US has significant effect on the TMJ pain [78].
Figure 10. Cavitation phenomenon.
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Another  experience is related to use of phonophoresis with ultrasound of high intensity and 
low frequency passing through the skin (hair follicles and sweat glands) with addition of an 
anti-inflammatory phytotherapy gel in treatment of Biceps Long Head tendinitis in rotator 
cuff disease compared to a Extracorporeal Shock Wave Therapy (ESWT) treatment of the rota-
tor cuff tendinitis.
At the present time, there are no specific and standard protocols for the application of ultra-
sound to the transdermal drug delivery, because of multiple variables of treatment such as 
frequency, method of delivery, molecular structure of the drug, patients’ age, thickness, and 
hydration of the skin.
It is definitely a treatment that offers advantages compared to the oral administration of 
anti-inflammatories.
Despite the contradictions in the various studies on mode of administration, frequency and 
drug use, almost all agree on the effectiveness of this therapeutic method in relieving pain and 
restoration of function that is impaired in different conditions affecting the musculoskeletal 
system [74].
6. Phytotherapy
Acute and chronic diseases of the musculoskeletal system represent about 40% of health 
demands. If you add to this the progressive increase in the average lifespan resulting in 
increased incidence of mechanical, metabolic and consumption alterations, that are the basis 
of chronic myofascial and joints’ diseases, it understands the interest toward an “complemen-
tary medicine.” In this context, phytotherapy and the search for natural substances that act on 
inflammation and pain fit perfectly.
Inflammation is a response model to the damage; it leads to accumulation of cells and exu-
dates in tissues harmed in to protect from further damage. Inflammation has been studied for 
thousands years to try to counteract the effects it has on the human body [79].
Phytotherapy is the use of plant-derived medications in the treatment or prevention of more 
inflammatory and noninflammatory diseases. Indeed medical herbalism which is character-
ized by an empirical approach, phytotherapy is a science-based medical practice. Numerous 
Figure 11. Frequencies of ultrasound and application area.
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trials and pharmacological studies of specific phytotherapeutic preparations exist. In some 
countries, it is considered sufficient to license phytotherapeutic products as medicines, 
whereas in other countries, phytotherapy is viewed as a form of traditional medicines.
The concept of phytotherapy was originated by French physician Henri Leclerc, who first used 
the term in 1913 and who published various editions of the Précis de phytothérapie the first 
in 1922. Successively, in 1934, the term Phytotherapy was used in common as a definition by 
Eric Frederick William Powell, an English expert of herbalism. Only in 1960, a German herb-
alist and physician Rudolf Fritz Weiss published Lehrbuch der Phytotherapie (1960; Herbal 
Medicine), which determined a definition of this topic in all Europe [80].
Only in the 1980s, the scientific research published in scientific article (as in journal 
Phytotherapy Research) with a definition in the medical-scientific field of phytotherapy 
began.
A commonly used in phytotherapy is standardization, which is the need to have a minimum 
of one or more active compounds or groups of plant extract compounds.
Natural products with anti-inflammatory activity have long been used as a folk remedy for 
inflammatory conditions such as fever, pain, migraine, and arthritis. The report of the British 
Nutrition Foundation offers a classification of phytochemicals useful information on products 
with anti-inflammatory properties [81].
Extensive scientific research revealed that curcumin has anti-inflammatory action [82].
The anti-inflammatory activity of curcumin is mainly due to the inhibition of arachidonic acid 
metabolism, cyclooxygenase (COX), lipoxygenase (LOX), interleukin (IL), tumor necrosis fac-
tor (TNF) and also due to the stabilization of the lysosomal membrane [83–85].
In the pathogenesis of arthritis sundry inflammatory cytokines (TNF, IL-1, IL-6), phlogosis 
enzymes (COX-2, 5-LOX, MMP-9) and adhesion molecules have a central role and almost all 
of this are synthesized following the gene transcription of NF-kB. Joe et al. investigated the 
effect of curcumin on acid glycoprotein in serum of rats with induced arthritis [86]. Treating 
inflammation in these rats with arthritis induced with curcumin per os, has been seen a 73% 
reduction in the levels of Gp A72.
The typical cartilage consumption that occurs in rheumatoid arthritis, is due to the action of 
matrix metalloproteinases (MMPs), whose MMP-1 and MMP-3 genes are over expressed in 
synovial fibroblasts of patients affected by this disease rheumatoid arthritis. Onodera et al. 
[87] have shown that curcumin blocks the upregulation of MMP mRNA.
Furthermore, curcumin can enhance the growth inhibitory and pro-apoptotic effects of cele-
coxib in synovial cells in OA as noted by Lev-Ari et al [88]. A synergistic effect was observed 
in the inhibition of cell growth when the cells were exposed to celecoxib combined with cur-
cumin. The inhibitory effect of the combination of these drugs on cell growth resulted in an 
increase of apoptosis induction. The use of celecoxib at lower concentrations and more secure 
in combination with curcumin can provide a combination of novel treatment for OA and 
other rheumatologic disorders.
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To relieve symptoms of arthritis is also used Lyprinol, extracted from green mussels from New 
Zealand, containing triglycerides, sterols, polar lipids and free fatty acids. Lyprinol showed a 
significant anti-inflammatory activity in induced polyarthritis in rats [89]. The mechanism by 
which the lyprinolo acts remains unclear. It certainly reduce proinflammatory LTB4 in human 
monocytes. Additionally, a human study showed that NZGLM reduces levels of TXB2, PGE2 
and IL-1β with a similar power to low doses of omega-3 supplement [90].
The first natural substance used as anti-inflammatory in rheumatoid arthritis and osteoarthri-
tis, was bromelain in 1964 [91]. It is an aqueous extract obtained from stem and fruit of the 
Pineapple plant. It has several beneficial effects, including the reversible inhibition of platelet 
aggregation. Currently, it is used mainly in acute inflammation and sports injuries. The anti-
inflammatory mechanism is due to increasing serum fibrinolytic activity, reduction in plasma 
fibrinogen levels, decreasing levels of PGE2, TXA2, reduction in bradykinin levels with sub-
sequent reduction in vascular permeability and thus edema; and modulating the adhesion 
molecules of the immune system cells.
In the treatment of muscle damage, Arnica is also widely used; also known as mountain daisy, 
mountain tobacco, and leopard’s bane, Arnica is a perennial herb of the family Asteraceae [92].
Lyss et al. demonstrated that helenalin, the most active compound from Arnica, inhibits the 
transcription factor nuclear factor kappa B (NF-kB) through the alteration and stabilization of 
NF-kB/inhibitor of kappa B complex (IkappaB) in cells T, B cells and epithelial cells and abol-
ish the expression of kappa B gene-driven. Later work showed that helenalin can inhibit the 
migration and chemotaxis of human neutrophils and activities of 5-lipoxygenase and leukot-
riene C4 synthase. As Lyss et al. postulated in 1997, Helenalin indirectly reduces the expres-
sion of NF-kB, acting on expression of surface receptors CD25, CD28, CD27, and CD120b that, 
if occupied, transduce the activation signal for NF-kB [93].
The activation of NF-kB promotes the release of proinflammatory cytokines and the recruit-
ment of local leukocytes, generating pain and phlogosis.
The Arnica ability to inhibit the activation of NF-kB nuclear transcription factors of activated 
T cells and pro-inflammatory cytokines IL-1b TNF-a are related with their contents, quantity, 
and quality of sesquiterpene lactones.
When you consider that muscle damage induced by exercise and delayed onset muscles sore-
ness (DOMS) are accompanied by a systemic inflammatory response that is responsible for 
initiating, amplifying and/or resolving of muscle damage, one can understand why arnica has 
a role in these situations.
Overall, Arnica (topical and/or oral formulations) showed reproducible clinical benefits, some 
of which are comparable with anti-inflammatory drugs such as diclofenac [93], ibuprofen, 
and corticosteroids [94], which are considered the therapy of choice for the treatment of osteo-
arthritis, postoperative edema, and bruising [95].
The Arnica topical use is supported by studies that prove its effectiveness in reducing the acute 
muscle pain induced by exercise,[96, 97] and in the symptomatic treatment of osteoarthritis.
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Local action is exerted on the muscle, calming the sensation of pain; in the joints, reducing the 
swelling and pain caused by rheumatic diseases; on the vascular district, reducing hematoma 
and bruising and protecting blood vessels.
7. Homeopathy
Homeopathy, from the greek ὅμοιος, omoios, “similar” and πάθος, pathos, “suffering,” was 
developed in the late 700s by a German doctor, Samuel Hahnemann, in an age when the 
symptoms were cured with “therapies” often more lethal than diseases, such as bloodlet-
ting and enemas. Hahnemann was convinced that the same substance  at high doses cause 
a disease in healthy people, instead, at infnitesimal doses could cure sick people. Also he 
claimed that diluting especially substances (“potentiation” obtained by the succession 
of serial dilutions) not only reduced or abolished the toxic effect, but also, paradoxically, 
increased their curative power [98]. Homeopathy is a pharmaceutical preparation that 
contains, in equal parts, different homeopathic dilutions prepared from the same tincture 
[99]. In Italy, homeopathy is regulated by normative reference for homeopathy Legislative 
Decree of 24 April 2006, no. 219 “Implementation of Directive 2001/83/EC (and subsequent 
amending Directives) on a Community code relating to medicinal products for human use, 
as well as the Directive 2003/94/EC. For preparing a homeopathic diluition, in fact, one starts 
from a basic substance which is then diluted and dynamized. A critical step is the prepara-
tion of the mother tincture, whose production technique is described in the French Official 
Pharmacopoeia (X edition 1983). The ratio between the dried product and water-alcohol 
mixture is 1:10. The degree of water-alcohol mixture varies in relation to the solubility of 
the products to be extracted: a plant with predominantly water-soluble active substances is 
lower with respect to the title of a substance with principles less water-soluble active. It will 
have to macerate for 21 days, while for an alcoholic tincture it takes 5–10 days. The effects 
of homeopathic medicines have been studied in numerous study with experimental inflam-
mation [100–103] Homeopathic clinical research has developed over the last twenty years 
with the increasingly greater use of modern medical methods (clinical trials, observational 
studies, statistic evaluations, computerized storage programs and instrumental or labora-
tory testing). For example, Atropa belladonna (Belladonna) is commonly used for treatment of 
local inflammation: it is prescribed for reducing severe pain, inflammation or any infection, 
especially on the upper part of the respiratory tract. Belladonna is most suitable to treat 
disorders of the heart, blood vessels, lungs as well as the neuropathic pain. The toxic juice 
of Atropa belladonna in homeopathic formulation is extremely diluted with alcohol in order 
to eliminate even the slightest trace of toxicity and to remove harmfulness. This procedure 
makes it suitable for human use [104, 105].
There are three extracts of Echinacea: E. pallida, E. angustifolia, and E. purpurea that are pro-
posed as phytoimmunostimulating agents and their activity is mainly directed toward the 
nonspecific cellular immune system [106] Echinacea angustifolia that is used for many years 
also in traditional medicine, acts in determining an increase of leukocyte activity, stimulation 
of phagocytosis, TNF production by macrophages and increase of T and B cell activity, as well 
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as gINF production by lymphocytes [107]. Furthermore, Echinacea has antioxidant effects and 
free radical scavenging capacities, related to the content in polyphenolic compounds. 
Echinacoside, chlorogenic acid, chicoric acid, cynarine and caffeic acid inhibit the production 
of free radicals and lipid peroxidation, classic inflammation consequence. All of this caffeoyl 
derived, are contained in Echinacea. Besides, echinacoside induce degradation of type III colla-
gen with a potential role in cicatrizacion and fibrosys treatment [108]. A series of step-by-step 
research trial about the biological effects of homeopathic Arnica montana, specially the Arnica 
montana 6cH, using animal models is presented in literature [109]. Arnica montana is a plant 
from the family Compositae native of East and Central Europe hills. Leaves, flowers, and 
roots contain tannins, flavonoids, lactones sesquirterpenic, alcohols and obviously helenalin 
which is the active principle best known [110]. It acts inhibiting the transcription factor NFκβ, 
like a corticoid steroids [111].  Trauma pain and oedema absorption are the main indications 
for the clinical and experimental use of this homeopathic preparation [94, 112–115].
Others studies show that Arnica montana 6cH is able to modulate the acute inflammatory 
process in rats, since it can increase lymphatic oedema absorption and local blood flow, as 
well as to promote the array of polymorphonuclear cell migration [116]. Four homeopathic 
remedies can be used for arthritis: causticum (6cH, 30cH) typically helpful in rheumatoid 
arthritis, this remedy is known for its anti-inflammatory action on the muscles, tendons, 
and nerves; calcarea carbonica (6cH, 30cH), this remedy has many disorders associated 
with calcium metabolism and is helpful in many cases of osteoarthritis; colchicum can be 
used for rheumatoid arthritis and gout for controlling pains in the small joints, especially 
the big toe, and minimal swelling; nux vomica (6cH, 30cH) in joint pains, especially in the 
knees [117].
These are only a few of the hundreds of homeopathic remedies that can be helpful in inflam-
matory conditions.
8. Topical application
The human epidermal permeabilities of different NSAIDs (salicylic acid, diethylamine salic-
ylate, indomethacin, naproxen, diclofenac and piroxicam) from aqueous solutions is depen-
dent on the drug’s lipophilicity [118]. Topical application can be applied over the site of 
injury or pain area like lumbar or cervical zone and its analgesic and anti-inflammatory 
effects are expressed in the underlying superficial or musculoskeletal soft tissue. This modal-
ity of administration of NSAIDs acts locally and is not dependent on systemic absorption 
and subsequent redistribution into peripheral tissues with significantly lower systemic side 
effects Furthermore, it is a direct access and it allows prolonged use above all in patients who 
cannot use no oral medications [95, 119–120]. Of the available formulations is the epolamine 
salt of diclofenac that offers specific advantages for topical administration. The surfactant 
property of diclofenac epolamine improves hydration of the stratum corneum so it increases 
surface tension at the interface between the skin and the topical pharmaceutical preparation, 
favouring absorption [121]. Diclofenac epolamine topical patch is indicated for treatment 
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of acute pain of minor strains, sprains, and contusions and as a home therapy in a complex 
rehabilitation project in soft tissue diseases (e.g., tendonitis, epicondylitis), or rheumatologic 
disorders (e.g., osteoarthritis, rheumatoid arthritis), or extra-articular pathologies (e.g., fibro-
sitis). Each adhesive patch contains 180 mg of diclofenac epolamine and inactive excipients, 
which enhance skin hydration and facilitate plaster adherence. Following the application of 
diclofenac twice daily for 5 days, were found peak plasma concentrations of 0.7–6.0 ng/mL at 
10–20 hours. In the bloodstream, diclofenac has a half-life of about 12 hours and it is widely 
linked to albumin [122]. Its metabolism is urinary and biliary excretion of the sulfate and 
glucuronide conjugates. In 19 clinical trials, tolerability and efficacy of the various topical 
formulations of diclofenac (1.5% diclofenac sodium solution, 1.16% diclofenac diethylamine 
gel, 140 mg diclofenac hydroxyethylpyrrolidine patch, and 2% diclofenac lecithin organogel) 
have been recently revised, whereas approximately 3000 patients treated [123]. Furthermore, 
Diclofenac sodium 1% gel is used commonly for the relief of pain due to osteoarthritis such 
as the knees and those of the hands. This product contains a variety of additional ingredients 
in the vehicle including isopropyl alcohol, propylene glycol, and water to assist in drug pen-
etration of the skin [124]. Topical administration is linked to local skin irritation or allergies 
[125].
Mg2+ may be one of these components because it has a significant role in energy metabolism 
via basic mitochondrial function, ATP transmembrane transport, muscle contraction or relax-
ation, membrane stability, and neuromuscular, cardiovascular, immune and hormonal func-
tions [126–129]. Mg2+ depletion has been reported to decrease antioxidant capacity, increase 
oxidative stress, and impair intracellular calcium homeostasis that result in swelling and 
structural damage to muscle cells [130].
Some study shows that transdermal application may be better accepted than oral applica-
tion in these patients with fibromyalgia for control of pain and inflammation because it is 
usually used a multitude of oral medications. Transdermal MgCl2 solution is ideal for use in transdermal applications because it is rapidly absorbed through the skin and, therefore, can 
rapidly increase low or depleted levels of magnesium in the body [31, 131]. Engen et al sug-
gest that transdermal Mg Cl2 applied twice daily (16 sprays of MgCl2 which equals 400 mg of magnesium) on the upper and lower limbs may be beneficial for patients with fibromyalgia 
[132].
9. Galenic formulations
A new galenic formulation has recently been developed. Galenic formulations with lower 
treatment burdens are associated with better patient compliance and persistence compared 
with older more burdensome modalities. Galenic formulations are characterized by low 
cost of the production system and the simple operative procedures; the possibility to adapt 
dosages and pharmaceutical forms to the patients’ needs and medical prescriptions; reduc-
tion in the use of counterfeit medicines in the settings where the Galenic laboratories are 
located [133]. It is a therapeutic aspect evolving, so it requires others studies over the next 
few years.
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10. Conclusion
This chapter gives an overview about the state of the art regarding the use of NSAIDs in 
physical and rehabilitation medicine, not only used by the classical routes of administration, 
but especially about the uses of these drugs through own means of this branch of medicine.
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